The negative headlines dominated today’s earlier news flow as Omicron variant uncertainty triggers risk aversion again. It is too early to speculate on whether it causes more...
Calling Omicron a COVID variant "of great concern," Regeneron CEO Leonard Schleifer argued Tuesday that new strains of the virus will keep appearing until there are methods to...
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Tuesday, November 30th. Please refresh for updates.Meta Platforms (NASDAQ:FB) stock fell 0.6% after...
Drugmaker Regeneron (REGN) is facing a problem that's plaguing many drugmakers these days. Specifically, the arrival of the omicron variant of COVID-19 is leaving...
Regeneron Shares Surge As Antibody Cocktail Cuts COVID Risk By 81.6%For the third time in about a month, another major pharmaceutical competitor has released a new COVID cure - in...
"The global health industry was worth $8.45 trillion in 2018 and global healthcare could reach over $10 trillion by 2022," according to PolicyAdvice a US insurance specialist. And...
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Neutral | Buy |
| Technical Indicators | Strong Sell | Sell | Strong Sell | Strong Sell | Strong Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 6.15 | 6.32 | 6.32 | 0.00 | 0.00% | 1.23M | London | |||
| 216.80 | 221.30 | 215.50 | -0.50 | -0.23% | 12.92M | London | |||
| 131.70 | 136.56 | 131.14 | -0.62 | -0.47% | 25.36M | London | |||
| 643.20 | 647.80 | 640.00 | +2.40 | +0.38% | 998.26K | London | |||
| 1,002.40 | 1,002.60 | 988.80 | +16.60 | +1.68% | 11.00M | London | |||
| 488.00 | 482.00 | 482.00 | -7.00 | -1.41% | 40.81K | London | |||
| 1,230.00 | 1,249.50 | 1,221.00 | -9.50 | -0.77% | 2.21M | London | |||
| 46.48 | 47.71 | 46.33 | -0.44 | -0.95% | 136.28M | London | |||
| 2,730.00 | 2,730.00 | 2,680.00 | +50.0 | +1.87% | 3.31K | London | |||
| 65.94 | 66.32 | 65.00 | +0.94 | +1.45% | 13.50M | London | |||
| 64.20 | 66.00 | 63.20 | -0.70 | -1.08% | 868.22K | London | |||
| 105.00 | 105.80 | 103.40 | +1.40 | +1.35% | 660.02K | London | |||
| 185.00 | 185.00 | 185.00 | 0.00 | 0.00% | 0.00 | London | |||
| 550.80 | 555.40 | 548.60 | -0.80 | -0.14% | 3.12M | London | |||
| 580.00 | 595.00 | 575.00 | -4.00 | -0.69% | 755.86K | London |